These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9283804)

  • 1. Insulin responses to oral glucose during 4-year treatment with nifedipine retard in hypertensive patients with and without NIDDM.
    Kazumi T; Hozumi T; Ishida Y; Yoshino G
    Diabetes Care; 1997 Sep; 20(9):1491. PubMed ID: 9283804
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics.
    Jasik M; Kasperska-Dworak A; Czyzyk A
    Diabetes Res Clin Pract; 1996 Jun; 33(1):59-66. PubMed ID: 8877277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment.
    Tentorio A; Ghilardi G; Pedroncelli A; Benco R; Stroppa S; Adib S; Gianola D; Pagani G
    Eur J Clin Pharmacol; 1989; 36(3):311-3. PubMed ID: 2663524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension.
    Giordano M; Matsuda M; Sanders L; Canessa ML; DeFronzo RA
    Diabetes; 1995 Jun; 44(6):665-71. PubMed ID: 7789631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension.
    Maccario M; Oleandri SE; Avogadri E; Rossetto R; Grottoli S; Procopio M; Camanni F; Ghigo E
    J Endocrinol Invest; 1998 Jan; 21(1):56-63. PubMed ID: 9633024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients.
    Masuo K; Mikami H; Ogihara T; Tuck ML
    Am J Hypertens; 1997 Jun; 10(6):600-10. PubMed ID: 9194505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-acting nifedipine.
    Gauthier B; Trachtman H
    Pediatr Nephrol; 1997 Dec; 11(6):786-7. PubMed ID: 9438668
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension.
    Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
    Diabetes Res Clin Pract; 1992 May; 16(2):137-43. PubMed ID: 1600852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse reactions to short-acting nifedipine in hypertensive crises.
    Spizzirri F; Rahman R
    Pediatr Nephrol; 1999 May; 13(4):366. PubMed ID: 10454793
    [No Abstract]   [Full Text] [Related]  

  • 10. A trial of the calcium antagonist nisoldipine in hypertensive non-insulin-dependent diabetic patients.
    Odigwe CO; McCulloch AJ; Williams DO; Tunbridge WM
    Diabet Med; 1986; 3(5):463-7. PubMed ID: 2951198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
    Derosa G; Mugellini A; Pesce RM; D'Angelo A; Maffioli P
    BMC Cardiovasc Disord; 2016 Apr; 16():66. PubMed ID: 27068332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
    Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients.
    Gill JS; Al-Hussary N; Zezulka AV; Pasi KJ; Atkins TW; Beevers DG
    Clin Ther; 1987; 9(3):304-10. PubMed ID: 3300989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifedipine and other calcium channel blockers.
    Pahor M
    Eur Heart J; 1997 Jan; 18(1):168. PubMed ID: 9049532
    [No Abstract]   [Full Text] [Related]  

  • 15. Prolonged QT interval and ventricular fibrillation after treatment with sublingual nifedipine for malignant hypertension.
    Peters FP; de Zwaan C; Kho L
    Arch Intern Med; 1997 Dec 8-22; 157(22):2665-6. PubMed ID: 9531240
    [No Abstract]   [Full Text] [Related]  

  • 16. [Is there a risk in treatment of hypertension with nifedipine?].
    Düsing R
    Internist (Berl); 1996 Sep; 37(9):939-41. PubMed ID: 8964691
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hypotensive efficacy and tolerability of combination of dihydropyridine and non-dihydropyridine calcium antagonists in the treatment of patients with arterial hypertension].
    Iskenderov BG; Burmistrova LF; Berenshteĭn NV; Lokhina TV
    Kardiologiia; 2007; 47(11):44-5. PubMed ID: 18260963
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of Ca channel blockers on glucose metabolism and insulin sensitivity].
    Shinshi Y; Ura N; Shimamoto K
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():320-3. PubMed ID: 15779395
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of early side effects with amlodipine and nifedipine retard in hypertension.
    Hosie J; Bremner AD; Fell PJ; James IG; Saul PA; Taylor SH
    Cardiology; 1992; 80 Suppl 1():54-9. PubMed ID: 1534716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nifedipine scare in hypertension: fact or fiction.
    Gambhir DS
    Indian Heart J; 1996; 48(3):227-9. PubMed ID: 8755005
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.